Bio Gene Technology Stock Fundamentals
| BGT Stock | 0.04 0.01 16.22% |
Bio Gene Technology fundamentals help investors to digest information that contributes to Bio Gene's financial success or failures. It also enables traders to predict the movement of Bio Stock. The fundamental analysis module provides a way to measure Bio Gene's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Bio Gene stock.
At this time, Bio Gene's Depreciation And Amortization is comparatively stable compared to the past year. Interest Expense is likely to gain to about 63.8 K in 2024, whereas Other Operating Expenses is likely to drop slightly above 2.5 M in 2024. Bio | Select Account or Indicator |
Bio Gene Technology Company Shares Outstanding Analysis
Bio Gene's Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Current Bio Gene Shares Outstanding | 201.36 M |
Most of Bio Gene's fundamental indicators, such as Shares Outstanding, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Bio Gene Technology is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
| Competition |
Bio Common Stock Shares Outstanding
Common Stock Shares Outstanding |
|
Based on the latest financial disclosure, Bio Gene Technology has 201.36 M of shares currently outstending. This is 11.54% higher than that of the Chemicals sector and 88.44% higher than that of the Materials industry. The shares outstanding for all Australia stocks is 64.79% higher than that of the company.
Bio Gene Technology Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Bio Gene's current stock value. Our valuation model uses many indicators to compare Bio Gene value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Bio Gene competition to find correlations between indicators driving Bio Gene's intrinsic value. More Info.Bio Gene Technology is rated fifth in return on equity category among its peers. It also is rated fifth in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Bio Gene's earnings, one of the primary drivers of an investment's value.Bio Shares Outstanding Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Bio Gene's direct or indirect competition against its Shares Outstanding to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Bio Gene could also be used in its relative valuation, which is a method of valuing Bio Gene by comparing valuation metrics of similar companies.Bio Gene is currently under evaluation in shares outstanding category among its peers.
Bio Fundamentals
| Return On Equity | -0.8 | |||
| Return On Asset | -0.45 | |||
| Current Valuation | 6.45 M | |||
| Shares Outstanding | 201.36 M | |||
| Shares Owned By Insiders | 43.33 % | |||
| Price To Book | 3.10 X | |||
| Price To Sales | 483.62 X | |||
| Revenue | 18.32 K | |||
| Gross Profit | 222.1 K | |||
| EBITDA | (2.97 M) | |||
| Net Income | (2.41 M) | |||
| Total Debt | 368.45 K | |||
| Book Value Per Share | 0.01 X | |||
| Cash Flow From Operations | (2.75 M) | |||
| Earnings Per Share | (0.01) X | |||
| Target Price | 0.37 | |||
| Beta | 0.71 | |||
| Market Capitalization | 8.86 M | |||
| Total Asset | 3.16 M | |||
| Retained Earnings | (19.64 M) | |||
| Working Capital | 2.59 M | |||
| Net Asset | 3.16 M |
About Bio Gene Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Bio Gene Technology's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Bio Gene using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Bio Gene Technology based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Total Revenue | 18.3 K | 17.4 K | |
| Cost Of Revenue | 319.8 K | 200.5 K |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Bio Stock Analysis
When running Bio Gene's price analysis, check to measure Bio Gene's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bio Gene is operating at the current time. Most of Bio Gene's value examination focuses on studying past and present price action to predict the probability of Bio Gene's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bio Gene's price. Additionally, you may evaluate how the addition of Bio Gene to your portfolios can decrease your overall portfolio volatility.